Real‑World Treatment Patterns in Endometrial Cancer in the Post-Immune Checkpoint Inhibitor and Post-Platinum-Based Chemotherapy Setting in the United States

INTRODUCTION: Immune checkpoint inhibitors (ICI), either following or in combination with platinum chemotherapy (PT), are routinely used to treat endometrial cancer (EC). Subsequently, a post-ICI and post-PT patient population is emerging with no approved therapy or guideline-recommended treatment approach for this setting. As novel therapies are being explored, it is critical to understand the patient characteristics and real-world treatment patterns in this setting. METHODS: This retrospective observational study used de-identified electronic health record data from the Flatiron Health database (2013-2026). Adult women with EC who had prior exposure to both ICI and PT and subsequently initiated a new regimen (the index line of therapy [LOT]) were included. The results were stratified by mismatch repair and microsatellite instability (MMR/MSI) status, and treatment patterns were summarized descriptively. RESULTS: A total of 564 women met the selection criteria, including 34 (6.0%) treated in the first LOT, 188 (33.3%) in the second LOT, 189 (33.5%) in the third LOT, and 153 (27.1%) in the fourth LOT or later. Among patients with deficient MMR/MSI-High (dMMR/MSI-H) tumors, post-ICI and post-PT regimens usually included hormonal therapy (18.0%) and ICI monotherapy (14.0%). Among patients with proficient MMR and microsatellite stable (pMMR/MSS) tumors, chemotherapy monotherapy (25.7%) and ICI plus tyrosine kinase inhibitor combinations (11.9%) were most frequent. A total of 228 patients (40.4%) received an ICI-containing regimen at the index LOT or a subsequent line, of whom 179 (78.5%) received a pembrolizumab-containing regimen, 21 (9.2%) a dostarlimab-containing regimen, and 28 (12.3%) other ICI-containing regimens. CONCLUSIONS: In EC, the post-ICI and post-PT patient population is growing, particularly in the second LOT and earlier settings. Treatment following ICI and PT exposure in EC was highly variable, with no dominant regimen identified regardless of MMR/MSI status.

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-11-13
DOI
https://doi.org/10.1007/s12325-026-03830-x
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‑World Treatment Patterns in Endometrial Cancer in the Post-Immune Checkpoint Inhibitor and Post-Platinum-Based Chemotherapy Setting in the United States

Angela K. Green, Srujitha Marupuru, Robin Meng, Christian Marth et al.
1 links
Advances in Therapy
Endometrial and Cervical Cancer Treatments
article

Real‑World Treatment Patterns in Endometrial Cancer in the Post-Immune Checkpoint Inhibitor and Post-Platinum-Based Chemotherapy Setting in the United States

Angela K. Green, Srujitha Marupuru, Robin Meng, Christian Marth, Vy Tran, Kathleen M. McClain, Robert J. Orlowski, Vimalanand S. Prabhu, Vicky Makker, Kirti Mirchandani, Ke Meng
article en

Abstract

INTRODUCTION: Immune checkpoint inhibitors (ICI), either following or in combination with platinum chemotherapy (PT), are routinely used to treat endometrial cancer (EC). Subsequently, a post-ICI and post-PT patient population is emerging with no approved therapy or guideline-recommended treatment approach for this setting. As novel therapies are being explored, it is critical to understand the patient characteristics and real-world treatment patterns in this setting. METHODS: This retrospective observational study used de-identified electronic health record data from the Flatiron Health database (2013-2026). Adult women with EC who had prior exposure to both ICI and PT and subsequently initiated a new regimen (the index line of therapy [LOT]) were included. The results were stratified by mismatch repair and microsatellite instability (MMR/MSI) status, and treatment patterns were summarized descriptively. RESULTS: A total of 564 women met the selection criteria, including 34 (6.0%) treated in the first LOT, 188 (33.3%) in the second LOT, 189 (33.5%) in the third LOT, and 153 (27.1%) in the fourth LOT or later. Among patients with deficient MMR/MSI-High (dMMR/MSI-H) tumors, post-ICI and post-PT regimens usually included hormonal therapy (18.0%) and ICI monotherapy (14.0%). Among patients with proficient MMR and microsatellite stable (pMMR/MSS) tumors, chemotherapy monotherapy (25.7%) and ICI plus tyrosine kinase inhibitor combinations (11.9%) were most frequent. A total of 228 patients (40.4%) received an ICI-containing regimen at the index LOT or a subsequent line, of whom 179 (78.5%) received a pembrolizumab-containing regimen, 21 (9.2%) a dostarlimab-containing regimen, and 28 (12.3%) other ICI-containing regimens. CONCLUSIONS: In EC, the post-ICI and post-PT patient population is growing, particularly in the second LOT and earlier settings. Treatment following ICI and PT exposure in EC was highly variable, with no dominant regimen identified regardless of MMR/MSI status.

Advances in Therapy
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Memorial Sloan Kettering Cancer Center (US), Innsbruck Medical University (AT), Universität Innsbruck (AT), Weill Cornell Medicine (US)
Merck, Regeneron Pharmaceuticals
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon